 |
|
|
|
|
New Screening Catches More Breast Cancers
|
| | | | Related Healthscout Videos | |
|
Page: << Prev | 1 | 2 | 3 Disparities also existed in the younger range (women aged 65 to 70) of this older group, who were less likely to have medical conditions precluding radiation therapy. Here, 71 percent of black women received potentially lifesaving radiation versus 81 percent of white women.
The largest disparities were evident in the East South Central region of the United States, the Pacific West and New England.
"What seems to be happening is that the use of conservative surgery and radiation opens the door for disparities to play a greater role in limiting access to care," Winer said. In this two-step process (surgery plus radiation), Winer added, "it is possible for women to fall through the cracks."
Text Continues Below
The final study addressed women with HER2-positive breast cancer, which traditionally has a worse prognosis than other forms of breast cancer.
Chemotherapy and treatment with Herceptin (trastuzumab) before surgery results in a "pathologic complete response," meaning no evidence of invasive disease in the breast or lymph nodes existed in many patients.
Patients who did not have this complete response were three times more likely to have a recurrence, the researchers from M.D. Anderson reported.
In about one-third of those not achieving a complete response, the cancer had converted from HER2-positive disease to HER2-negative disease, meaning it was no longer responsive and had possibly become resistant to HER2-specific therapies such as Herceptin.
The authors stressed the importance of reassessing tissue for HER2 status after preoperative treatment.
More information
Visit the National Cancer Institute for more on breast cancer.
Page: << Prev | 1 | 2 | 3
|
Copyright © 2008 ScoutNews, LLC. All rights reserved.
Last updated 9/4/2008
|
|
SOURCES: Sept. 3, 2008, teleconference with Eric Winer, M.D., spokesman, American Society of Clinical Oncology, professor of medicine, Harvard Medical School and director, breast oncology center, Dana-Farber Cancer Institute, Boston; Carrie B. Hruska, M.D., research fellow, department of radiology, Mayo Clinic, Rochester, Minn.; Lisa K. Jacobs, M.D., assistant professor, surgery, Johns Hopkins University, Baltimore; Grace L. Smith, M.D., Ph.D., postdoctoral fellow, department of radiation oncology, University of Texas M.D. Anderson Cancer Center, Houston; Sept. 3, 2008, presentations, American Society of Clinical Oncology's 2008 Breast Cancer Symposium, Washington, D.C.
|
.gif)
